Government agencies evaluate the costs and benefits of new regulatory proposals. A credible evidence base is needed to support and document the economic value of new technologies and therapeutic approaches. Our clients need careful cost-benefit and cost-effectiveness analyses for successful reimbursement submissions.
What we do
Working on a wide range of therapies and outcomes, we draw on a specialist team to deliver state-of-the-art cost-benefit and cost-effectiveness analyses for government or industry audiences applying economic impact models and non-market valuation methods.
Clients receive robust evidence-based models characterizing the economic value of their technology, intervention or approach.
Health economic information affects how patients, providers, payers, and regulators make decisions. Clients, globally, need robust, reliable, and high quality analyses for HTA submissions.
What we do
We leverage a range of expertise acquired from working on several HTAs in various therapeutic areas to help moving your product to market. Our experts provide strategic advice and apply appropriate methods to answer your specific research question. We also guide the development of novel approaches to identify relevant subgroups that can lead to new opportunities for your product.
We work with clients to put together effective and highly competitive HTA submissions, maximizing their likelihood of success.